Abstract
Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 (EC 3.4.14.5.) is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types, whose physiological functions are largely unknown. Protein dimerisation should be required for catalytic activity and glycosylation of the enzyme could impact on its physiological functions. The dimeric glycoprotein ADCP has been found linked to adenosine deaminase (ADA) whose relationship with lymphocyte maturation-differentiation is well-established. Since implicated in the regulation of the biological activity of hormones and chemokines, such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, DPP4 inhibition offers a new potential therapeutic approach for type 2 diabetes mellitus, as monotherapy and adjunct therapy to other oral agents. The clinical use of presently available orally active inhibitors of DPP4, however, has been associated with side effects that have been in part attributed to the inhibition of related serine proteases, such as DPP8 and DPP9. Indeed, it is noteworthy that CD26 has a key role in immune regulation as a T cell activation molecule and in immune-mediated disorder. All-cause infections were increased after sitagliptin treatment. It is noteworthy that the effects of DPP4 inhibition on the immune system have not been extensively investigated. So far, only routine laboratory safety variables have been measured in published randomised controlled trials. The review summarises present knowledge in the field and suggests some potential directions of future research.
Keywords: Serine peptidase, dipeptidyl peptidase-4, CD26, DPP4 inhibitors, type 2 diabetes mellitus
Current Medicinal Chemistry
Title: Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
Volume: 16 Issue: 23
Author(s): E. Matteucci and O. Giampietro
Affiliation:
Keywords: Serine peptidase, dipeptidyl peptidase-4, CD26, DPP4 inhibitors, type 2 diabetes mellitus
Abstract: Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 (EC 3.4.14.5.) is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types, whose physiological functions are largely unknown. Protein dimerisation should be required for catalytic activity and glycosylation of the enzyme could impact on its physiological functions. The dimeric glycoprotein ADCP has been found linked to adenosine deaminase (ADA) whose relationship with lymphocyte maturation-differentiation is well-established. Since implicated in the regulation of the biological activity of hormones and chemokines, such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, DPP4 inhibition offers a new potential therapeutic approach for type 2 diabetes mellitus, as monotherapy and adjunct therapy to other oral agents. The clinical use of presently available orally active inhibitors of DPP4, however, has been associated with side effects that have been in part attributed to the inhibition of related serine proteases, such as DPP8 and DPP9. Indeed, it is noteworthy that CD26 has a key role in immune regulation as a T cell activation molecule and in immune-mediated disorder. All-cause infections were increased after sitagliptin treatment. It is noteworthy that the effects of DPP4 inhibition on the immune system have not been extensively investigated. So far, only routine laboratory safety variables have been measured in published randomised controlled trials. The review summarises present knowledge in the field and suggests some potential directions of future research.
Export Options
About this article
Cite this article as:
Matteucci E. and Giampietro O., Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme, Current Medicinal Chemistry 2009; 16 (23) . https://dx.doi.org/10.2174/092986709788803114
DOI https://dx.doi.org/10.2174/092986709788803114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Long-Term Intraperitoneal Injection of Thyrotropin-Releasing Hormone (TRH) on Aging- and Obesity-Related Changes in Body Weight, Lipid Metabolism, and Thyroid Functions
Current Aging Science Natural Antioxidants in Wheat Sprout Extracts
Current Organic Chemistry Aqueous Extract of Anabasis aretioides Ameliorates Streptozotocininduced Diabetes Mellitus in Rats
The Natural Products Journal New Horizons in Diabetes Therapy: The Angiogenesis Paradox in Diabetes: Description of the Problem and Presentation of a Unifying Hypothesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design Treatment Options for Post-Transplantation Diabetes Mellitus
Current Diabetes Reviews Radiological Presentation of H1N1 Influenza in the 2017 Outbreak in India and Correlation with Patient Outcome
Current Respiratory Medicine Reviews Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier
Current Diabetes Reviews A Novel Combined Pharmacophore Mapping and Quantitative Structure Selectivity Relationship Analysis for the Development of Potent and Selective Human Aldose Reductase Inhibitors
Current Computer-Aided Drug Design Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) Serum Adiponectin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters The Potential Role of Antioxidants in Metabolic Syndrome
Current Pharmaceutical Design Preventive Antiretroviral Therapy in Non-Thalassemia Carrier Infants Exposed to Mother-to-Child Transmission of HIV Decreases Cord and After Delivery Red Blood Production without Altering the Development of Hemoglobin
Current HIV Research Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design The Role of Lifestyle Change in the Prevention and Treatment of NAFLD
Current Pharmaceutical Design